Anne-Sophie Chalandon | Head of Global Public Affairs, Rare Diseases and CGT Policies
SANOFI

Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and molecular biology, holds a PhD in Business and Management from HEC Paris Business School and a Master’s in health policy at Paris Sciences Po. In her current role, she is Head of Global Rare Diseases and CGT Policy at Sanofi, lead the IFPMA RD group, and co-chair the EFPIA OMP group. Since 2017, she leads an internal digital project construct collectively with the French rare diseases community to address the diagnostic delay in rare diseases named UniR. Externally, she is member of several public-private initiates such as Screen4care, Together4RD, Moonshot, the Global Commission, IRDIRC, … With her current role at IFPMA she is strongly involved in the advance of the UN agenda for People Living with Rare Diseases. Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and molecular biology, holds a PhD in Business and Management from HEC Paris Business School and a Master’s in health policy at Paris Sciences Po. In her current role, she is Head of Global Rare Diseases and CGT Policy at Sanofi, co-lead the IFPMA RD group. Since 2017, she leads an internal digital project construct collectively with the French rare diseases community to address the diagnostic delay in rare diseases named UniR. Externally, she is member of several public-private initiates such as Screen4care, Together4RD, Moonshot, the Global Commission, IRDIRC, … With her current role at IFPMA she is strongly involved in the advance of the UN agenda for People Living with Rare Diseases.

Appearances:

Pre-Congress Workshops - Monday 27th October @ 14:00

Public Private Partnerships in Rare Disease: Ideas to action

This workshop will explore innovative approaches to cross-sector partnerships in the EU rare disease landscape. Participants will examine successful case studies that highlight innovative collaborations in rare disease research and diagnostics, showcasing how diverse stakeholders can work together to overcome challenges. The session will highlight partnerships that have demonstrated significant impact across the European rare disease ecosystem. By fostering knowledge exchange and promoting innovative strategies, this workshop aims to inspire and equip attendees with actionable insights to enhance multi-sector collaboration and ultimately improve outcomes for rare disease patients across Europe.

Interdisciplinary Collaboration: Tools and Insights for Successful Rare Disease Partnerships
IHI RealiseD - compRehensive mEthodological Approach to cLinical trIalS in (ultra-)rarE Diseases
Newborn Screening in the EU: Historical Perspectives and Future Horizons

Moderator: Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies, SANOFI

Mathieu Boudes, Senior Advisor, FIPRA

Vinciane Pirard, Medical - SAI, Chair of IRDiRC Companies Constituent Committee (CCC), Sanofi

Alicia Granados, Global Head Scientific Advocacy and Insights, Sanofi

Kit Roes, Professor, RadboudUMC

Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut

Stefaan Sansen, Scientific Director, Sanofi Genzyme

Session led by:

Danielle Dong, Global Medical Scientific Advocacy Lead, Rare Disease, Sanofi

Andrew Thomson, Consultant, Regnitio

Rita Francisco, Survey Project Manager, EURORDIS